blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3383883

EP3383883 - SALTS OF CONJUGATES FOR CANCER THERAPY [Right-click to bookmark this link]
StatusExamination is in progress
Status updated on  09.04.2021
Database last updated on 22.08.2024
FormerRequest for examination was made
Status updated on  07.09.2018
FormerThe international publication has been made
Status updated on  15.06.2017
Most recent event   Tooltip11.10.2023New entry: Renewal fee paid 
Applicant(s)For all designated states
BioSight Ltd.
3 Hayarden Street
Airport City, P.O.Box 1083
Lod 7019802 / IL
[2019/44]
Former [2018/41]For all designated states
BioSight Ltd.
1 Hayarden St. Airport City
P.O.B 1083
Lod 7019802 / IL
Inventor(s)01 / GENGRINOVITCH, Stela
HaEla 208
2010800 Kfar Hanania / IL
 [2018/41]
Representative(s)Pearl Cohen Zedek Latzer Baratz UK LLP
The Gridiron Building
One Pancras Square
London N1C 4AG / GB
[N/P]
Former [2018/41]Becker Kurig Straus
Patentanwälte
Bavariastrasse 7
80336 München / DE
Application number, filing date16870129.001.12.2016
[2018/41]
WO2016IL51287
Priority number, dateUS201562262428P03.12.2015         Original published format: US 201562262428 P
WO2016IL5007725.01.2016         Original published format: PCT/IL2016/050077
US201662370257P03.08.2016         Original published format: US 201662370257 P
[2018/41]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2017094011
Date:08.06.2017
Language:EN
[2017/23]
Type: A1 Application with search report 
No.:EP3383883
Date:10.10.2018
Language:EN
The application published by WIPO in one of the EPO official languages on 08.06.2017 takes the place of the publication of the European patent application.
[2018/41]
Search report(s)International search report - published on:IL08.06.2017
(Supplementary) European search report - dispatched on:EP21.06.2019
ClassificationIPC:A61K31/7068, A61P35/00, A61P35/02, A61P31/12, A61K47/54, C07H19/06, C07H19/09
[2019/30]
CPC:
C07H19/09 (EP,US); C07H19/067 (IL); A61K47/542 (EP,IL,RU,US);
A61P35/00 (RU); A61P35/02 (EP,RU,US); A61P35/04 (EP,US);
C07H19/06 (EP,IL,RU,US) (-)
Former IPC [2018/41]C07H19/06, C07H19/067, A61P35/00, A61P35/02, A61K31/7068, A61K47/50
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2018/41]
TitleGerman:SALZE VON KONJUGATEN ZUR KREBSTHERAPIE[2018/41]
English:SALTS OF CONJUGATES FOR CANCER THERAPY[2018/41]
French:SELS DE CONJUGUÉS EN CANCÉRO-THÉRAPIE[2018/41]
Entry into regional phase22.05.2018National basic fee paid 
22.05.2018Search fee paid 
22.05.2018Designation fee(s) paid 
22.05.2018Examination fee paid 
Examination procedure22.05.2018Examination requested  [2018/41]
22.05.2018Date on which the examining division has become responsible
20.01.2020Amendment by applicant (claims and/or description)
09.04.2021Despatch of a communication from the examining division (Time limit: M04)
17.08.2021Reply to a communication from the examining division
11.11.2022Despatch of a communication from the examining division (Time limit: M04)
20.03.2023Reply to a communication from the examining division
Fees paidRenewal fee
12.12.2018Renewal fee patent year 03
13.12.2019Renewal fee patent year 04
14.12.2020Renewal fee patent year 05
30.11.2021Renewal fee patent year 06
13.10.2022Renewal fee patent year 07
11.10.2023Renewal fee patent year 08
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[I]JPH0859688  (MITSUI TOATSU CHEMICALS) [I] 1-4,8-11 * compound 8 * * claim 1 *;
 [I]US2011275590  (GENGRINOVITCH STELA [IL], et al) [I] 1-15 * paragraph [0125] * * example 17 * * claims 2,3,7-10,12-17 *;
 [I]  - Anonymous, "Study Evaluating the Safety and Efficacy of Astarabine in Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia (BSTPHASE1-01)", ClinicalTrials.gov, Internet, (20150909), pages 1 - 7, URL: https://clinicaltrials.gov/ct2/show/record/NCT02544438?view=record, (20190603), XP055593324 [I] 1-15 * the whole document *
International search[Y]US7989188  (GENGRINOVITCH STELA [IL], et al) [Y] 1-46 * Whole document *;
 [Y]WO2015178265  (NIPPON KAYAKU KK [JP]) [Y] 1-46 * Whole document *;
 [Y]CN101812105  (UNIV SHENYANG PHARMACEUTICAL) [Y] 1-46 * Whole document *;
 [A]US2014227282  (NISHITANI SHINOBU [JP], et al) [A] 1-38 * Whole document *;
 [Y]  - SINGH, V.K. et al., "Development of reversible glutamine conjugate of methotrexate for enhanced brain delivery.", Medicinal Chemistry Research, vol. 24, no. 2, (20150000), pages 624 - 635, (20140720), XP 035427193 [Y] 1-46 * Whole document *
 [Y]  - MING-JI JIN et al., "Synthesis and In-vitro Evaluation of N4-Amino Acid Derivatives of Cytarabine for Improving the Oral Delivery of Cytarabine.", Journal of Pharmaceutical Investigation, vol. 38, no. 4, (20080000), pages 255 - 259, (20080430), XP 055387237 [Y] 1-46 * Whole document *
 [X]  - HASABELNABY, S. et al., "Synthesis, chemical and enzymatic hydrolysis, and aqueous solubility of amino acid ester prodrugs of 3-carboranyl thymidine analogs for boron neutron capture therapy of brain tumors.", European journal of medicinal chemistry, (20120000), vol. 55, pages 325 - 334, XP 055387239 [X] 1-46 * Whole document, especially Scheme 3, compounds 17 and 18; par. 4.1.6.b, 4.1.6.7 and 4.1.6.8 *
 [A]  - WECHTER, W. J. et al., "Nucleic acids. 16. Orally active derivatives of ara-cytidine.", Journal of medicinal chemistry, (19760901), vol. 19.8, pages 1013 - 1017, XP005538724 [A] 1-38 * Whole document *
 [A]  - LIU, B. et al., "Synthesis and evaluation of anti-tumor activities of N4 fatty acyl amino acid derivatives of 1-beta-arabinofuranosylcytosine.", European journal of medicinal chemistry, (20090000), vol. 44, no. 9, pages 3596 - 3600, XP 026322187 [A] 1-46 * Whole document *
 [A]  - PRADEEPKUMAR L. PATEL., "Targeting GRP78 in Cancer with Nucleic Acid Bioconjugates.", Ph.D. Thesis., Seton Hall University South Orange, NJ, USA, (20140800), XP 055387248 [A] 1-46 * Scheme 2.2, compound 2.6; Paragraph 2.3.6; Fig. 2.10 *
 [A]  - CHHIKARA B.S. et al., "Development of cytarabine prodrugs and delivery systems for leukemia treatment.", Expert opinion on drug delivery, (20100000), vol. 7, no. 12, pages 1399 - 1414, XP 055387250 [A] 1-38 * Fig. 3 *
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.